Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1

Cardiovascular Drugs and Therapy

Volumn 23, Issue 4, 2009, Pages 301-306

  Milio, Glauco ^a   Novo, Giuseppina ^a   Genova, Caterina ^a   Luigi Almasio, Piero ^a   Novo, Salvatore ^a   Pinto, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Critical limb ischemia; L propionyl carnitine; Maximum walking distance; PGE 1; Rest pain

Indexed keywords

DROMOS; KETOROLAC; PROPIONYLCARNITINE; PROSTAGLANDIN E1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLAUDICATION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG INFUSION; FEMALE; HUMAN; LIMB ISCHEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN ULCER; TREATMENT DURATION; VOMITING; WALKING;

AGED; ALPROSTADIL; CARDIOTONIC AGENTS; CARNITINE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISCHEMIA; LEG; LEG ULCER; MALE; MIDDLE AGED; PAIN; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 69249230903     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6178-3     Document Type: Article

References (34)

1. G Brevetti C Angelini M Rosa, et al. 1991 Muscle carnitine deficiency in patients with severe peripheral vascular disease Circulation 84 1490 3
2. LR Wiseman RN Brogden 1998 Propionyl-L-carnitine Drugs Aging 12 243 8
3. WR Hiatt 2004 Carnitine and peripheral arterial disease Amer NY Acam Sci 1033 92 8
4. WR Hiatt 2004 Treatment of disability in peripheral arterial disease: new drugs Curr Drug Target Cardiovasc Haematol Disord 4 227 31
5. S Signorelli G Malaponte L Di Pino D Di Grandi G Pennisi MC Mazzarino 2001 Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration Pharmacol Res 44 305 9
6. L Loffredo P Pignatelli R Cangemi, et al. 2006 Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment J Vasc Surg 44 525 30
7. L Loffredo A Marcoccia P Pignatelli, et al. 2007 Oxidative stress mediated arterial dysfunction in patients with peripheral arterial disease Eur Heart J 28 608 12
8. G Brevetti C Diehm D Lambert 1999 European multicenter study on propionyl-L-carnitine in intermittent claudication J Am Coll Cardiol 34 1618 24
9. G Brevetti F Di Lisa S Perna, et al. 1996 Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy Circulation 93 1685 9
10. G Brevetti S Perna C Sabba, et al. 1992 Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double blind, cross-over study Eur Heart J 13 251 5
11. WR Hiatt JG Regensteiner MA Creager, et al. 2001 Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication Am J Med 110 616 22
12. G Brevetti S Perna C Sabba VD Martone A Di Iorio G Barletta 1997 Effect of propionyl-L-carnitine on quality of life in intermittent claudication Am J Cardiol 79 777 80
13. G Persico B Amato G Aprea P Cerfolio AK Markabaoui 1995 The early effects of intravenous L-propionyl carnitine on ulcerative throphic lesions of the lower limbs in arteriopathic patients: a controlled randomized study Drug Exp Clin Res 21 187 98
14. S Signorelli L Di Pino MP Costa D Digrandi G Pennisi G Marchese 2001 Efficacy of L-Propionyl Carnitine in the treatment of chronic critical limb ischemia Clin Drug Invest 21 555 61
15. S Novo G Coppola G Milio 2004 Critical limb ischemia: definition and natural history Curr Drug Target Cardiovasc Haematol Disord 4 219 25
16. T Simmet BA Peskar 1988 Prostaglandin E1 and arterial occlusive disease: pharmacological consideration Eur J Clin Invest 18 549 54
17. G Milio V Cospite M Cospite 2003 Effects of PGE-1 in patients suffering from arterial occlusive disease Min Cardioang 51 311 6
18. G Milio C Minà V Cospite PL Almasio S Novo 2005 Efficacy of the treatment with Prostaglandin E-1 in venous ulcers of the lower limbs J Vasc Surg 42 304 8
19. H Sinzinger P Fitscha O Wagner J Kaliman W Rogatti 1987 Prostaglandin E1 decreases activation of arterial smooth muscle cells Lancet II 156 7
20. S Marchesi L Pasqualini R Lombardini, et al. 2003 Prostaglandin E1 improves endothelial function in critical limb ischemia J Cardiovasc Pharmacol 41 249 53
21. K Matsui U Ikeda Y Muratami T Yoshiota K Shimada 2003 Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease Am Heart J 145 330 3
22. B Palumbo A Oguocho H Sinzinger 2003 Prostaglandin E1 temporarily decreases adhesion molecules Am Heart J 145 12 3
23. JA Dormandy RB Rutherford 2000 TransAtlantic inter-Society Consensus (TASC). Management of peripheral arterial disease J Vasc Surg 31 S1 296
24. D Lapi V Cimini L Bruno, et al. 2003 Effect of L-Propionyl-carnitine on molecules of adhesion during ischemia-reperfusion Min Cardioangiol 51 71 3
25. GM Andreozzi R Martini RM Cordova A D'Eri 2003 Ischemia-reperfusion and cytoprotection by L-Propionyl-Carnitine in man Min Cardioangiol 51 74 5
26. AZ Reznick VE Kagan R Ramsey, et al. 1992 Antiradical effects in L-propionylcarnitine protection of the heart against ischaemia-reperfusion injury: the possible role of iron chelation Arch Biochem Biophys 296 394 401
27. D Moher KF Schulz DG Altman for the CONSORT group 2001 The CONSORT statement: revisede recommendation for improving the quality of reports of parallel group randomized trials JAMA 285 1987 91
28. S Sakaguchi 1983 Prostaglandin E 1 intrarterial infusion therapic in patients with ischemic ulcer of the extremities Int Angiol 3 39 42
29. L Nogren A Alwmark KA Angkvist B Hedberg D Bergqvist R Takolander 1990 A stable prostacyclin analog (iloprost) in the treatment of ischemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomized multicenter study Eur J Vasc Surg 4 463 7
30. G Bandiera M Forletta FM Di Paola C Cirielli 2003 PGE-1 short term therapy in critical lower limb ischemia Int Angiol 22 58 63
31. S Makita M Nakamura A Ohhira S Itoh K Hiramori 1997 Effects of prostaglandin E1 perfusion on limb haemodynamics and vasodilatory response in patients with arteriosclerosis obliterans Cardiovasc Drug Ther 11 441 8
32. MR Mehrabi N Serbecic F Tamaddon, et al. 2003 Clinical benefit of prostaglandin E1 treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infracted myocardium Biomed Pharmacother 57 173 8
33. F Violi L Loffredo A Marcoccia 2004 Antioxidants in peripheral arterial disease Curr Drug Target Cardiovasc Haematol Disord 4 461 5
34. BL Bendermacher EM Willigendael JA Teijink MH Prins 2005 Medical management of peripheral arterial disease J Thromb Haemost 3 1628 37